Sintilimab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | Anti-PD-1 monoclonal antibody IBI308[1] |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Sintilimab, sold under the brand Tyvyt among others, is a medication used to treat Hodgkin's disease,[2] and has been approved in China.[3]
It is a fully human IgG4 monoclonal antibody[4] that binds to programmed cell death protein 1.[5]
It was jointly developed by Innovent Biologics[6] and Eli Lilly.[7]
- ^ "anti-PD-1 monoclonal antibody IBI308". NCI Drug Dictionary. National Cancer Institute. 2011-02-02.
- ^ "Antibody Drug Conjugates Market Growth Forecast Analysis by Manufacturers, Regions, Type and Application to 2026". Reuters. October 24, 2018.
- ^ "NMPA Approves Tyvyt For Hodgkin's lymphoma Read". Asian Scientist Magazine. January 9, 2019.
- ^ Ying K, Xu N, Jiang H, Liu Y, Zhou H, Wang S (2018). "OA08 Efficacy and Safety of Sintilimab Combined with 1st Line Chemotherapy in Advanced Squamous Cell Non-small Cell Lung Cancer". Journal of Thoracic Oncology. 13 (12): S1047. doi:10.1016/j.jtho.2018.10.018. Retrieved Dec 1, 2018.
- ^ Hoy SM (February 2019). "Sintilimab: First Global Approval". Drugs. 79 (3): 341–346. doi:10.1007/s40265-019-1066-z. PMID 30742278. S2CID 59945274.
- ^ "Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company". SEC.gov. December 20, 2018.
- ^ "Sintilimab - Eli Lilly/Innovent Biologics". Adis Insight. Springer Nature Switzerland AG. 28 March 2019.